GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Clearside Biomedical
Clearside Biomedical develops treatments for eye diseases using its unique drug delivery technology. Its stock price is a bet on this platform. Its price is volatile and driven by news of clinical trials and partnerships.
Share prices of companies in the market segment - Pharma eyes
Clearside Biomedical develops drugs to treat retinal diseases using its proprietary suprachoroidal microinjection technology. We've categorized it under "Pharma: Eyes." The chart below shows how the market is evaluating innovative drug delivery methods in ophthalmology.
Broad Market Index - GURU.Markets
Clearside Biomedical is a biotech company that has developed a unique technology for delivering drugs directly to the back of the eye. As an innovator, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Clearside's performance to assess the state of this sector.
Change in the price of a company, segment, and market as a whole per day
CLSD - Daily change in the company's share price Clearside Biomedical
For Clearside Biomedical, Inc., which develops drugs for eye diseases, daily volatility reflects sensitivity to clinical trial data. This metric is key for assessing risks in this innovative field.
Daily change in the price of a set of shares in a market segment - Pharma eyes
Clearside Biomedical, Inc. is a biotech company. This chart shows the sector's extreme volatility. Comparison with CLSD, which focuses on eye disease treatments, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Clearside Biomedical is a biotech company specializing in the treatment of eye diseases. Its stock price depends on clinical trial success and regulatory approvals. These events create unique price movements that contribute to overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Clearside Biomedical
For Clearside Biomedical, year-over-year performance is a story about its unique technology for delivering drugs to the back of the eye. Its market capitalization growth over the past 12 months reflects both the success of its own drug and licensing agreements with major pharmaceutical companies seeking to use its microinjector for their ophthalmic products.
Annual dynamics of market capitalization of the market segment - Pharma eyes
Clearside Biomedical, Inc. is a biopharmaceutical company specializing in the treatment of eye diseases using its unique drug delivery technology. This chart shows how the market views its innovative platform, clinical trial results, and the commercial potential of its products.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Clearside Biomedical, which develops therapies for eye diseases, is a biotech story where clinical data is king. Its year-over-year performance relative to the market is a series of sharp moves driven by trial news. Success could lead to explosive growth, completely defying the overall market stagnation.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Clearside Biomedical
Clearside Biomedical is a biopharmaceutical company focused on eye diseases. Its monthly performance is driven by clinical and regulatory events. News about its drug trial results and interactions with the FDA drive strong share price movements.
Monthly dynamics of market capitalization of the market segment - Pharma eyes
Clearside Biomedical develops treatments for retinal diseases using its proprietary microinjection technology, which enables precise drug delivery. The graph below illustrates the overall dynamics in the ophthalmic pharmaceutical sector, where innovative delivery methods play a key role.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks, especially in a complex field like ophthalmology, often take on a life of their own, reacting to trial news. The chart below shows general market trends. Is Clearside Biomedical following this trend, or are its R&D activities creating a unique story?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Clearside Biomedical
Clearside Biomedical, which develops therapies for posterior segment eye diseases using its unique drug delivery system, is extremely news-sensitive. Weekly stock price movements are a direct response to the release of clinical trial data and partnership decisions with major pharmaceutical companies.
Weekly dynamics of market capitalization of the market segment - Pharma eyes
Clearside Biomedical operates in the highly competitive ophthalmology sector, where investor sentiment drives global sentiment. The success or failure of a major blockbuster drug influences expectations for all companies in this niche. The chart shows how CLSD fares in this competitive landscape compared to other developers.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Clearside Biomedical, as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how CLSD shares can rise or fall on their own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
CLSD - Market capitalization of the company Clearside Biomedical
Clearside Biomedical's chart is a focused bet on treating diseases of the back of the eye. The company has developed a unique injector for delivering drugs to the retina. Its market cap dynamics reflect how investors view this technology and its partnerships with major pharmaceutical companies.
CLSD - Share of the company's market capitalization Clearside Biomedical within the market segment - Pharma eyes
Clearside Biomedical has developed a unique method for delivering drugs to the back of the eye using its patented microneedle. Its share of the ophthalmology sector is based on this technology. The graph shows the demand for its suprachoroidal injection method for treating retinal diseases.
Market capitalization of the market segment - Pharma eyes
Clearside Biomedical develops drugs to treat retinal diseases using a unique microinjection technology. The chart below shows the market capitalization of the ophthalmology pharmaceutical sector. This represents a market where innovations in drug delivery methods could change the standard of care.
Market capitalization of all companies included in a broad market index - GURU.Markets
Clearside Biomedical has developed a unique technology for delivering drugs to the back of the eye using microinjections. Its market capitalization is a bet on this method. The chart below shows the economic weight of companies with innovative drug delivery platforms.
Book value capitalization of the company, segment and market as a whole
CLSD - Book value capitalization of the company Clearside Biomedical
Clearside Biomedical's book value is based on a unique technology for eye treatment. Its foundation consists of patents for the SCS Microinjector®, which delivers drugs to the suprachoroidal space of the eye, and capital for R&D. The chart below shows how the company is building its financial base around this innovative platform.
CLSD - Share of the company's book capitalization Clearside Biomedical within the market segment - Pharma eyes
Clearside Biomedical relies on its R&D labs to develop eye medications. The S_BCap_Seg graph shows its share of scientific infrastructure, reflecting its focus on ophthalmology research.
Market segment balance sheet capitalization - Pharma eyes
Clearside Biomedical develops therapies for retinal diseases. Its unique drug delivery system is its core asset. A book value chart shows that its value is based on intangible assets (patents, R&D) rather than manufacturing capacity.
Book value of all companies included in the broad market index - GURU.Markets
Clearside Biomedical's assets represent a unique technology for eye treatment. The company's book value reflects its manufacturing capabilities for creating patented microinjectors that deliver medication precisely to the back of the eye. This provides the foundation for safer and more effective treatment of retinal diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Clearside Biomedical
Clearside Biomedical develops drugs for the treatment of eye diseases through injections into the suprachoroidal space. Its book value is small. Its market capitalization is based on its patented microinjector and a portfolio of drugs that could change the standard of ophthalmological therapy.
Market to book capitalization ratio in a market segment - Pharma eyes
Clearside Biomedical develops methods for delivering drugs to the back of the eye. Its value lies in its patented microinjection technology. The chart shows the market premium for its innovative approach to treating eye diseases compared to its tangible assets.
Market to book capitalization ratio for the market as a whole
Clearside Biomedical develops drugs for the treatment of eye diseases using its proprietary microinjection technology. The company's value lies in this unique delivery system. The chart shows how the market values the technology, which can improve the efficacy and safety of treatment, not just the molecule itself.
Debts of the company, segment and market as a whole
CLSD - Company debts Clearside Biomedical
Clearside Biomedical, a company specializing in the treatment of eye diseases, uses debt to finance its clinical programs. This chart shows the funding it is raising to develop and test its unique platform for delivering drugs directly to the back of the eye, which requires significant R&D investments.
Market segment debts - Pharma eyes
Clearside Biomedical develops drugs to treat posterior segment diseases using its proprietary microinjection technology. This focused approach requires significant investment in clinical research. This chart shows its financial position at the clinical development stage and its dependence on external funding.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Clearside Biomedical
Clearside Biomedical develops methods for delivering drugs to the back of the eye. This chart shows how the company funds its innovative research. In the highly specialized field of ophthalmology, debt can accelerate clinical trials, but any negative results could jeopardize the company's financial viability.
Market segment debt to market segment book capitalization - Pharma eyes
Clearside Biomedical develops methods for delivering drugs to the back of the eye. This chart for the ophthalmology-focused biotech industry shows how much capital it raises for R&D. It helps understand how the company's financial position is typical for this highly specialized and research-intensive field.
Debt to book value of all companies in the market
Clearside Biomedical develops drugs to treat retinal diseases using its proprietary microinjection technology. This chart, showing the market's debt-to-book value ratio, is important for assessing the investment climate in biotech. The market's willingness to finance companies with innovative drug delivery platforms determines Clearside's future.
P/E of the company, segment and market as a whole
P/E - Clearside Biomedical
Clearside Biomedical is developing methods for delivering drugs to the back of the eye to treat retinal diseases. This chart reflects the faith in its innovative technology. Its value shows how much investors are willing to invest in its unique microinjector, which promises more precise and effective therapy than traditional methods.
P/E of the market segment - Pharma eyes
Clearside Biomedical is a biotech company. This chart shows the average P/E ratio for the biotech sector. A company's P/E is higher than average, indicating that investors view its eye drug delivery technology as particularly promising and poised to capture a significant market share.
P/E of the market as a whole
Clearside Biomedical has developed a technology for delivering drugs to the suprachoroidal space of the eye, allowing for more precise targeting of the retina. This chart shows the sentiment in the pharmaceutical sector. The company's valuation depends on the success of its own development and the extent to which its technology is licensed by other companies for drug delivery.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Clearside Biomedical
Clearside Biomedical develops drugs for the treatment of eye diseases using its proprietary suprachoroidal drug delivery technology. The chart shows future revenue expectations, which depend on the success of clinical trials and the acceptance of this innovative delivery method by ophthalmologists.
%20P%2FE%20Clearside%20Biomedical&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Clearside-Biomedical&v=1772532432987 "Chart of the company's future (projected) P/E Clearside Biomedical")
Future (projected) P/E of the market segment - Pharma eyes
Clearside Biomedical develops drugs to treat retinal diseases using its proprietary suprachoroidal drug delivery technology. This chart shows how its future revenue expectations compare to the industry average, reflecting its innovative approach to ophthalmology.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-eyes&v=1772532433008 "Future (projected) P/E graph of the market segment - Pharma eyes")
Future (projected) P/E of the market as a whole
Clearside Biomedical develops medications for the treatment of eye diseases using its patented suprachoroidal microinjection technology. This innovative drug delivery method is crucial for the company's success. The company's success depends on the results of trials and the acceptance of its technology by ophthalmologists.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772532433042 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Clearside Biomedical
Clearside Biomedical is a biopharmaceutical company developing treatments for posterior segment diseases of the eye. It uses its proprietary microinjection technology to deliver drugs directly to the disease site. While in the development stage, it incurs significant R&D expenditures. This chart reflects its investment in the development of innovative treatments.
Profit of companies in the market segment - Pharma eyes
Clearside Biomedical, Inc. is a biopharmaceutical company that has developed an innovative method for delivering drugs to the back of the eye using microinjections. This chart shows the profitability of the ophthalmology segment. Its unique technology could become a platform for treating various retinal diseases. The company's success depends on partnerships and drug approvals.
Overall market profit
Clearside Biomedical develops and commercializes treatments for serious eye diseases. The company's success depends on the effectiveness of its proprietary drug delivery technology and clinical trial results. This gross profit chart illustrates the macroeconomic backdrop against which ophthalmological innovations like Clearside's create their own growth story.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Clearside Biomedical
Clearside Biomedical develops drugs to treat eye diseases using its proprietary suprachoroidal microinjection technology. This chart reflects analysts' future revenue expectations, which depend on the success of clinical trials and commercialization of this innovative method of drug delivery to the retina.
%20profit%20of%20the%20company%20Clearside%20Biomedical&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Clearside-Biomedical&v=1772532433440 "Graph of future (projected) profit of the company Clearside Biomedical")
Future (predicted) profit of companies in the market segment - Pharma eyes
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing drug delivery to the posterior segment of the eye. This chart shows profitability projections for the ophthalmology pharmaceutical segment. It reflects expectations for innovative treatments for retinal diseases that could improve the vision of millions.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-eyes&v=1772532433458 "Graph of future (predicted) profits of companies in a market segment - Pharma eyes")
Future (predicted) profit of the market as a whole
Clearside Biomedical develops treatments for eye diseases. For a biotech company at this stage, the market's profit forecast is an indicator of capital availability. An optimistic forecast, as seen in the chart, suggests that investors will be more willing to fund risky but promising clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772532433479 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Clearside Biomedical
Clearside Biomedical develops treatments for eye diseases using its proprietary microinjection technology. A company with approved products, with its P/S, reflects investors' perceptions of the commercial success of its technology and its potential to become a standard in ophthalmology.
P/S market segment - Pharma eyes
Clearside Biomedical develops treatments for eye diseases using its proprietary microinjection technology, which delivers drugs directly to the site of disease. This chart shows how investors view their innovative delivery platform, their portfolio of ophthalmic drug candidates, and their future potential.
P/S of the market as a whole
Clearside Biomedical develops drugs to treat eye diseases using its suprachoroidal injection technology. The company's revenue comes from partner fees and royalties. This chart illustrates the average revenue estimate, which helps understand how the market values the revenue of a biotech company with an innovative drug delivery platform.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Clearside Biomedical
Clearside Biomedical is developing methods for delivering drugs directly to the back of the eye, enabling the treatment of retinal diseases. This graph reflects investor expectations for future revenue from its unique technology and drugs, which could become a new standard in ophthalmology.
%20P%2FS%20Clearside%20Biomedical&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Clearside-Biomedical&v=1772532433896 "The graph of the company's future (projected) P/S Clearside Biomedical")
Future (projected) P/S of the market segment - Pharma eyes
Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing treatments for retinal and posterior segment diseases using its proprietary drug delivery platform. This chart shows how the market perceives the future potential of its innovative ophthalmology products, comparing it to other companies in the sector.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-eyes&v=1772532434072 "Future (projected) P/S market segment graph - Pharma eyes")
Future (projected) P/S of the market as a whole
Clearside Biomedical has developed a unique technology for delivering drugs to the back of the eye via microinjections. This allows for more effective treatment of retinal diseases. This chart shows overall revenue projections, and CLSD exemplifies how innovations in drug delivery methods can dramatically improve treatment.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772532434094 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Clearside Biomedical
Clearside Biomedical is a biopharmaceutical company focused on treating eye diseases. Its revenue in this chart is generated not from direct sales, but from royalties and license fees from partners who use its patented technology to deliver drugs to the back of the eye. Growth depends on the success of these partners' products.
Sales of companies in the market segment - Pharma eyes
Clearside Biomedical is a biopharmaceutical company focused on treating eye diseases. This chart segments its revenue by showing royalties from its drug delivery technology and royalties from partners. This reflects its partnership-based business model.
Overall market sales
Clearside Biomedical develops methods for delivering drugs to the back of the eye. The company's success depends on its proprietary technology and clinical trial results. This market summary chart does not apply to Clearside, whose value is determined by scientific advances and its potential to treat serious eye diseases.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Clearside Biomedical
Clearside Biomedical develops drugs to treat eye diseases using its proprietary suprachoroidal drug delivery technology. Its revenue forecast depends on the success of its drugs. This chart shows how analysts assess the commercial potential of its innovative treatment method.
%20sales%20of%20the%20company%20Clearside%20Biomedical&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Clearside-Biomedical&v=1772532434364 "Schedule of future (projected) sales of the company Clearside Biomedical")
Future (projected) sales of companies in the market segment - Pharma eyes
Clearside Biomedical develops drugs for the treatment of eye diseases using its proprietary suprachoroidal drug delivery technology. This chart shows projected revenue for the ophthalmology segment. It helps assess demand for innovative treatments, which is important for the commercialization of Clearside's unique technology.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-eyes&v=1772532434411 "Schedule of future (projected) sales of companies in the market segment - Pharma eyes")
Future (projected) sales of the market as a whole
Clearside Biomedical develops drugs for the treatment of eye diseases using its proprietary suprachoroidal drug delivery technology. The company's success depends on clinical trial results. This graph of overall market expectations reflects the investment climate, which is important for funding innovative approaches in ophthalmology.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772532434431 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Clearside Biomedical
Clearside Biomedical develops and commercializes methods for delivering drugs to the back of the eye. This chart shows how the company monetizes its unique technology. Its profitability depends on successfully licensing its platform to other pharmaceutical companies and on sales of its own products.
Market segment marginality - Pharma eyes
Clearside Biomedical develops and markets medications for the treatment of eye diseases using its proprietary suprachoroidal injection technology. This chart illustrates the average profitability in the ophthalmic pharmaceutical sector, allowing one to assess how Clearside's unique drug delivery system can provide a commercial advantage.
Market marginality as a whole
Clearside Biomedical, Inc. develops drugs to treat eye diseases using its proprietary technology for delivering drugs to the back of the eye. This overall revenue chart does not reflect the specifics of its business, which focuses on solving complex medical problems and is dependent on clinical trial results.
Employees in the company, segment and market as a whole
Number of employees in the company Clearside Biomedical
Clearside Biomedical is a biopharmaceutical company that has developed a unique technology for delivering drugs to the back of the eye. The growth of its commercial and medical teams, as shown in the graph, is due to licensing its technology and advancing its own drugs through clinical trials.
Share of the company's employees Clearside Biomedical within the market segment - Pharma eyes
Clearside Biomedical, Inc. is a biopharmaceutical company specializing in the treatment of eye diseases. This chart highlights its innovative approach to ophthalmology. It illustrates the number of ophthalmologists and researchers working on a unique technology for delivering drugs directly to the back of the eye that Clearside is bringing together to fight blindness.
Number of employees in the market segment - Pharma eyes
Clearside Biomedical, Inc. is a biopharmaceutical company developing methods for delivering drugs to the back of the eye. This chart shows employment in ophthalmic pharmaceuticals. The growing number of specialists here reflects breakthroughs in the treatment of retinal diseases and the need for innovative, less invasive drug delivery methods.
Number of employees in the market as a whole
Clearside Biomedical, Inc. is a biopharmaceutical company specializing in the treatment of eye diseases. Ophthalmology is a large and innovative market due to the aging population. This graph reflects overall employment, and such companies contribute to the development of medical technologies, creating a demand for qualified specialists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Clearside Biomedical (CLSD)
Clearside Biomedical is an ophthalmology company with a unique drug delivery technology. This chart shows how the market values this intellectual capital. The high cost per employee is a premium for an innovative method that has the potential to become a standard in eye treatment and generate huge revenues.
%20of%20the%20company%20Clearside%20Biomedical%20(CLSD)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Clearside-Biomedical-CLSD&v=1772532434748 "Chart of market capitalization per employee (in thousands of dollars) of the company Clearside Biomedical (CLSD)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma eyes
Clearside Biomedical specializes in treating eye diseases using its proprietary injectable technology. Its market value per employee reflects the value of this innovative drug delivery method. This high figure reflects investors' belief that this technology will become the standard in ophthalmology.
%20by%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-eyes&v=1772532434778 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma eyes")
Market capitalization per employee (in thousands of dollars) for the overall market
Clearside Biomedical is developing drugs to treat eye diseases using its proprietary microinjection technology. This chart shows how the market is evaluating both the drugs in development and their unique delivery technology, which could become a platform for many other drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772532434827 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Clearside Biomedical (CLSD)
Clearside Biomedical is a biotech company focused on treating retinal diseases. Its key technology is a proprietary drug delivery system (SCS Microinjector). This chart shows how successfully the company is licensing its technology and advancing its R&D programs using its scientific and commercial teams.
%20Chart%20Clearside%20Biomedical%20(CLSD)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Clearside-Biomedical-CLSD&v=1772532434862 "Company Profit Per Employee (in thousands of dollars) Chart Clearside Biomedical (CLSD)")
Profit per employee (in thousands of dollars) in the market segment - Pharma eyes
Clearside Biomedical develops drugs to treat eye diseases using its proprietary suprachoroidal microinjection technology. This chart highlights the value of their innovative delivery method. It shows how improving the drug delivery method can create a product with high commercial value and potential profitability in ophthalmology.
%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-eyes&v=1772532434877 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma eyes")
Profit per employee (in thousands of dollars) for the market as a whole
Clearside Biomedical develops treatments for eye diseases using its proprietary suprachoroidal drug delivery technology (SCS Microinjector). This chart reflects the R&D costs per employee required to advance this innovative delivery technology and drugs through clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772532434892 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Clearside Biomedical (CLSD)
Clearside Biomedical, a company specializing in the treatment of eye diseases, demonstrates the effectiveness of its commercial strategy in this chart. Revenue per employee is driven by sales of its products and licensing agreements. The growth of this indicator indicates the recognition of its technology by ophthalmologists.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Clearside-Biomedical-CLSD&v=1772532435007 "Sales chart per company employee Clearside Biomedical (CLSD)")
Sales per employee in the market segment - Pharma eyes
Clearside Biomedical (CLSD) is a biopharmaceutical company specializing in the treatment of retinal diseases using its proprietary drug delivery technology (SCS Microinjector®). This chart shows the average revenue per employee in the pharmaceutical segment. Comparing CLSD to this benchmark demonstrates how efficiently they license their technology and commercialize their drugs.
Sales per employee for the market as a whole
Clearside Biomedical (CLSD) is a biotech company focused on treating eye diseases. The company has an approved product (Xipere). This metric demonstrates how successfully their sales team is promoting this highly specialized drug to ophthalmologists. Growth is an indicator of market acceptance.
Short shares by company, segment and market as a whole
Shares shorted by company Clearside Biomedical (CLSD)
Clearside Biomedical is developing methods for delivering drugs to the back of the eye (the retina) using a specialized microneedle. This chart illustrates skepticism about their technology. "Bearers" are betting that their method will prove too complex, unsafe, or offer no advantages over standard intraocular injections.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Clearside-Biomedical-CLSD&v=1772532435278 "Short Shares Chart for the Company Clearside Biomedical (CLSD)")
Shares shorted by market segment - Pharma eyes
Clearside Biomedical (CLSD) is a biotech company that owns the SCS Microinjector technology for delivering drugs to the back of the eye (for retinal treatments). This chart highlights the pessimism in the sector. The surge in short positions in the industry is a bet that the delivery system itself is a poor business. Investors doubt CLSD's technology will become standard and fear competition from new, longer-acting drugs.
Shares shorted by the overall market
Clearside (CLSD) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing CLSD won't be able to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Clearside Biomedical (CLSD)
Clearside Biomedical is a pharmaceutical company specializing in the treatment of retinal diseases. It's a niche biotech. This chart shows the approval "pulse." The "temperature" of investor interest "heats up" as the FDA approval approaches or strong clinical trial data for their specific ophthalmic drugs.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Clearside-Biomedical-CLSD&v=1772532435373 "RSI 14 indicator chart for the company's stock Clearside Biomedical (CLSD)")
RSI 14 Market Segment - Pharma eyes
Clearside Biomedical is a company specializing in ophthalmology. Their unique feature is their patented suprachoroidal microinjector (SCS Microinjector), which delivers medication to the back of the eye. This graph measures the overall momentum in the ophthalmic medical device sector. It helps assess whether this entire niche segment is overheated.
RSI 14 for the overall market
Clearside (CLSD) is a biotech R&D company. Like everyone in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CLSD (Clearside Biomedical)
Clearside Biomedical (CLSD) has developed a unique platform for delivering drugs to the back of the eye (via the suprachoroidal space). This chart shows the average target price. It reflects analysts' confidence in this innovative microinjection technology and its potential in ophthalmology.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CLSD-Clearside-Biomedical&v=1772532435494 "A chart showing analyst consensus forecasts for the expected stock price. CLSD (Clearside Biomedical)")
The difference between the consensus estimate and the actual stock price CLSD (Clearside Biomedical)
Clearside Biomedical is a pioneer in the treatment of eye diseases. Their signature feature isn't so much their drugs as their unique technology (SCS Microinjector®) for delivering therapy to the hard-to-reach space at the back of the eye. This chart shows the growth potential analysts see. This gap reflects their belief that this delivery platform will become standard and licensed by pharmaceutical giants.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CLSD-Clearside-Biomedical&v=1772532435555 "A chart showing the difference between the consensus forecast and the actual stock price. CLSD (Clearside Biomedical)")
Analyst consensus forecast for stock prices by market segment - Pharma eyes
Clearside Biomedical is a pioneer in eye care. The company has developed a microinjector for delivering drugs to the hard-to-reach back of the eye (the suprachoroidal space). This chart reflects the overall expectations of ophthalmology analysts and shows how confident experts are in this new drug delivery technology.
Analysts' consensus forecast for the overall market share price
Clearside Biomedical is a biotech company specializing in the treatment of retinal diseases. Their signature technology is a unique technology (SCS Microinjector) for delivering drugs to hard-to-reach areas of the eye. This chart shows the overall risk appetite in the market. For Clearside, whose value lies in their technology, this overall optimism is crucial for funding clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Clearside Biomedical
Clearside Biomedical is a pioneer in the eye. They don't so much develop new drugs as they do new delivery methods: their signature feature is a patented microneedle (SCS) that delivers medication directly into the back of the eye (suprachoroidally). This graph is a summary of their R&D, reflecting their progress in clinical trials and their partnerships with major pharma.
AKIMA Market Segment Index - Pharma eyes
Clearside Biomedical (CLSD) revolutionized ophthalmology with its SCS Microinjector platform. It enables drug delivery directly to the back of the eye (the suprachoroidal space) to treat retinal diseases. The chart shows the segment average, helping investors assess how this unique delivery technology compares to the average.
The AKIM Index for the overall market
Clearside Biomedical is an ophthalmology company that has developed a microinjector for delivering drugs into the suprachoroidal space of the eye. This chart, which reflects the market average, provides background information. It helps assess how this delivery platform and its proprietary drugs compare to overall macroeconomic trends.
